J.P. Morgan Sticks to Their Buy Rating for Ultragenyx Pharmaceutical, Inc. (RARE)

By Ryan Adsit

In a report issued on August 1, Cory Kasimov from J.P. Morgan maintained a Buy rating on Ultragenyx Pharmaceutical, Inc. (RAREResearch Report), with a price target of $75. The company’s shares closed on Friday at $55.66.

According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 1.8% and a 42.7% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., ACADIA Pharmaceuticals Inc, and Global Blood Therapeutics.

Currently, the analyst consensus on Ultragenyx Pharmaceutical, Inc. is a Strong Buy with an average price target of $79, implying a 41.9% upside from current levels. In a report issued on August 2, Wedbush also initiated coverage with a Buy rating on the stock with a $75 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $90.98 and a one-year low of $37.44. Currently, Ultragenyx Pharmaceutical, Inc. has an average volume of 430.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.